Our History

Introducing the footsteps of inno.N in creating a healthy world and a story of innovation.

History

Company History

Introducing the footsteps of inno.N in creating a healthy world and a story of innovation.

A new start for the next century, opening a new chapter
in the pharmaceutical business.

A New Beginning for our 100- year journey

Our pioneering ideas create a new future for the pharmaceutical industry.

history_04
image_history_2020_2@mobile

300억

04.2020
Changed our company name to inno.N, marking a new beginning of our journey to become a leading global pharmaceutical industry.

2020

image_history_2020_1

02.2020
Launched the K-CAB.

Achieved revenue of 35.9 billion won within just 11 months.

P-CAB MEGA HIT

image_history_2019_3

2019

A New Beginning

We found our way to more creations.

11.2019
Received ‘ISO 37001’Certification of Global
Anti-Corruption Management System Established the industry’s largest corporate compliance policies.

image_history_2019_2@mobile

11.2019
Launched tablet-form CONDITION

CONDITION
INNOVATION

image_history_2019_1

03.2019
Launched Korea's 30th new drug K-CAB.

P-CAB NEW HIT

image_history_2018_3@mobile

2018

A New Beginning

07.2018
‘K-CAB‘Tab. (Ingredient name: Tegoprazan), Successfully in-house developed a new drug for gastroesophageal reflux disease, licensed by the Ministry of Food and Drug Safety
Korea’s No.30 New Drug

A NEW BEGINNING
OF P-CAB

image_history_2018_2@mobile
image_history_2018_1

01.2018
Achieved 'AA' rating for the Corporate Compliance Program

Out-licensed the second-generation EPO 'CJ-40001'
(a renal anemia treatment) technology to NCPC GeneTech in China

BUILDING NEW
COMPANY

image_history_2017_6

2017

A great leap towards the global market

inno.N aspires to reach beyond Korea to the global market

09.2017
Out-licensed the second-generation EPO 'CJ-40001
(a renal anemia treatment) technology to YL Biologics in Japan

image_history_2017_5

05.2017
Opened inno.N’s representative office in Vietnam (as of May 1)

04.2017
The foundation’s third-year anniversary

The 2nd Self-Compliance Day

image_history_2017_3

03.2017
Signed a MOU for 2017 Volunteer Work with Seoul Volunteer Center

image_history_2016_1

2016

Secure the future’s innovative technology through Open Innovation.

Milestone

Reached KRW 400 billion in sales

12.2016
SeokHee KANG (CEO of inno.N) was appointed as Self Compliance Manager

image_history_2016_3
image_history_2016_2

09.2016
Hosted the R&D Open Innovation Forum, attended by multiple business ventures from the U.S and Europe

Launched Korea’s first fixed-dose combination IMD for hypertension, ‘MACHKHAN'

image_history_2016_4@mobile

08.2016
Launched LUKIO

Held the launch event of the fixed-dose combination IMD for hypertension, ‘MACHKHAN’

Signed a MOU with Seoul Voluntary Center for Employees & Executives Voluntary Work

image_history_2016_5
image_history_2016_deco_2

2016.7
Launched the new version of HUTGAESOO

image_history_2016_6

2016.4
Hosted the R&D Open Innovation Forum with many business ventures from the U.S and Japan

image_history_2016_8
image_history_2016_7

2016.4
The foundation’s second-year anniversary of foundation
Established Self Compliance Day (4.1)

2ND ANNIVERSARY

image_history_2016_9
image_history_2016_deco_3

2016.3
Released the first TV Advertisement for ‘CONDITION’ in Vietnam

image_history_2010_1

2015

2015.10
Developed a new treatment for GERD ˝CJ-12420(Tegoprazan)˝, Transferred such a technology to Shandong Luoxin Pharmaceutical Group Stock Co., Ltd

image_history_2010_2
image_history_2010_3

2014

Launched ‘VOGMET’, a fixed-dose combination IMD for diabetes

Established inno.N Corporation

Debuted CONDITION in 3 different countries (China, Vietnam, and Japan)

history2010

2012

2012.05
Won the Beautiful Architecture Award for Cheongwon-gun Office for Osong Plant
`HUTGAESOO` became the No.1 dulcis drink in market share (2012. Nielsen Research)

Upgraded `CONDITION` to `HUTGAE CONDITION` in celebration of its 20th anniversary

image_history_2010_5
image_history_2010_6@mobile
Milestone

Reached KRW 400 billion in sales

2011

Launched ‘MOSAONE’, ‘ABELTAN’, and ‘LUKAIR’

2011.12
Anti-hangover drink `CONDITION` was designated as the `global leading product` by the Ministry of Knowledge & Economy'

Launched `CLOSONE`, a fixed-dose combination for antithrombotic therapy

Formed a joint R&D partnership with Bioleaders to develop anti-cancer drugs and vaccines

image_history_2010_7

2010

2010.03
Completed the construction of manufacturing buildings for oral APIs at Daeso Plant

2010.12
Completed the construction of Osong Plant under international standards

Launched `HEPCURE`

Launched `CONDITION HUTGAESOO (Hovenia Dulcis)`, a beverage.

Lead the market with R&D

inno.N became recognized as the trailblazer in Korea’s pharmaceutical industry by means of investment in continuous R&D.

history_03
image_history_2000_1
image_history_2000_deco_group

2009

2009.09
Strategic partnership for injectable solution business (Medi Pharma Plan)
Signed a MOU with the Traditional Medicine Center of Chungbuk Technopark to develop therapeutic ingredients and new drugs

Successfully penetrated the CNS market
Formed a co-promotion/marketing alliance on `SINGULAIR` with MSD Korea and launched `LUKAIR`
Launched `HUTGAE CONDITION POWER`

image_history_2000_2

2008

2008.07
Signed a joint-investment agreement with `Neuralstem` (a U.S. based stem-cell company)
Commenced the construction of a globally competitive plant in Osong Bio-Health Science Technopolis (with an investment worth KRW 150 billion)

Condition Joint giúp cả gia đình giảm nỗi lo xương khớp.

2007

Reached revenue of KRW 300 billion

image_history_2000_4

2006

2006.08
Acquires and merges with Hanil Pharmaceutical

image_history_2000_6
image_history_2000_5@mobile

2003

2003.06
Registered `PSEUDOVACCIN`, a pseudomonas aeruginosa vaccine & Korea`s No.7 new drug

Launched an anti-hyperlipidemic medication `SIMVASTA`(the first generic drug of simvastatin)

NEW
PRODUCTS

image_history_2000_7

2002

Established a hepatitis B vaccine plant and began exporting to Myanmar

Launched `CEFMENOXIME`, a cephalosporin antibiotic (sterile product)

image_history_2000_deco_3

2002

Advanced R&D and overseas business activities by establishing CJ CheilJedang Pharma New Jersey office

Launched `CEFOTIAM`, a cephalosporin antibiotic

Developed a fluid (I.V. solution) stabilization technology and developed multiple applications into current products

image_history_2000_8

2000

2000.02
Established OBU (Oncology Business Unit) and launched the new antiemetic `CAMPTO`, officially expanding the company’s reach to the anticancer medicine marketư

CANCER UNIT

With the launch of home-grown pharmaceutical products, inno.N opens a new chapter in the industry.

inno.N opened its new chapters in business by successfully localizing many drugs while unlocking USD 100 million in exports, the first in the domestic industry to do so.

history_02
image_history_1990_1@mobile

1990

1999.03
'Epokine' receives the Chang Yeongsil Prize

1999.02
The Daeso Plant receives certification for outstanding compliance with standards for the production and quality management of active pharmaceutical ingredients
(i.e. certification for BGMP, or Bulk Good Manufacturing Practices)

image_history_1990_2
image_history_1990_3

1998

1998.02
'Epokine', a new drug to treat anemia, is launched (the first of its kind in Korea and the third to be launched worldwide)

Reached 1 hundred million dollars in exported revenue, the first in Korea’s pharmaceutical industry to do so and launched a Cepha antibiotic ‘CEFTAZIDIME’.

image_history_1990_4
history_1997

1997

Co-developed a diagnostic reagent for epidemic hemorrhagic fever using genetic engineering technology with the National Institutes of Health (first in the world)

1997.04
Developed chicken pox vaccine - Launched `LEGIOFREE` (legionella remover)
Received ‘New Technology’ label (KT Label) for `LEGIOFREE`
Won the Prime Minister Award at the Excellent Patent Product Contest for Pseudomonas Aeruginosa vaccine
Launched antidiabetic `BASEN`

history_1995

1995

1995.09
`CITOPCIN` injectable received “New Technology” label (KT Label) and won Chang Young-sil Award
Developed the world’s first Pseudomonas Aeruginosa vaccine

image_history_1990_5@mobile

1993

Launched the cephalosporin antibiotic `CEFTRIAXONE`
Injectable fluids was certified as KGMP (Korea Good Manufacturing Practice)
Hepatitis B vaccine `HEPACCINE-B` was certified by WHO and delivered overseas for use by UN

image_history_1990_6
image_history_1990_7@mobile
Milestone

Reached KRW 100 billion in sales

1992

1992.11
Launched the cephalosporin antibiotic `CEFTRIAXONE`
Injectable fluids was certified as KGMP (Korea Good Manufacturing Practice)

1992.05
Hepatitis B vaccine `HEPACCINE-B` was certified by WHO and delivered overseas for use by UN

history_02

1991

Initiated the production of `7-ACA`, API for Cepha antibiotics

image_history_1990_8

1990

Completed the construction of the manufacturing plant (Daeso Plant) for APIs

FACTORY
DAESO

The beginning of our journey to create a healthier world

inno.N started as Pharmaceutical BU of CJ CheilJedang Corp. in 1984.

history_01
history_1986

1986

1986.12
The Icheon Plant completes its construction

image_history_1980_1

1985

1985.12
'Hepaxin-B', a vaccine for Hepatitis B is developed using domestic technologies only and launched in the market

image_history_1980_3

1984

1984.06
Acquired Yupung Pharmaceuticals
Started our business in pharmaceuticals and established a research institute
Established a U.S.-based R&D center (ETI)
Developed interferon for human lymphocytic cells